03.30.26 -- What If The U.S. Government Stopped Funding Biotech?

Rising demand for complex TIDES therapies is shifting manufacturing expectations, driving adoption of continuous processing, digital tools, stronger supply strategies, and greener, scalable synthesis.

Reliable temperature‑controlled storage, monitoring, and safeguards keep sensitive materials stable from fill to patient, protecting quality, preventing degradation, and ensuring safety.

A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.

Turn your inconsistent bioassays into GMP-validated, high-reliability platforms — just like we helped a biopharma partner cut failure rates from ~25% to <1%.

Explore how biopharma organizations can design and operate clinical supply systems that absorb complexity while maintaining control and consistency.

This resource provides a clear roadmap for delivering advanced sterile injectable therapies with confidence, meeting both regulatory demands and patient needs without compromise.

A fully integrated single‑site model unifies development, manufacturing, formulation, fill‑finish, and quality oversight to reduce handoff risk and speed progression from API to sterile drug product.

Bispecific antibodies (bsAbs) offer transformative therapeutic potential through dual-target engagement, but their complex structure presents significant manufacturing challenges.

Join this roundtable of biopharmaceutical professionals as they share their insights to help you navigate important quality and planning decisions for the progression of your biologic.

See the ways to design and de-risk molecules, streamlining the path to GMP manufacturing and clinical trials, and case studies that provide insight into key activities.

ADC manufacturing requires specialized expertise, single‑use systems, precise filtration, aseptic filling, and integrated lyophilization to ensure stability, safety, and consistent clinical‑grade production.

Accelerated cell line development delivers high-titer biologics in weeks, supporting diverse modalities with robust analytics, scalable productivity, and proven stability across 60+ generations.

Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex therapies.